Pharsight

Parsabiv generic

Parsabiv is an etelcalcetide-based drug owned by Kai Pharms Inc. It was first authorized for market use on 07 February, 2017. The drug is available in solution;intravenous dosage forms and has a total of 7 patents.

When will Parsabiv generic be available?

The generics of Parsabiv are projected to be released after 27 June, 2034 which is the expiry date of the last patent. The opportunity for filing drug patent challenges against Parsabiv begins from 2021-02-07.

Parsabiv uses

Parsabiv is used in the treatment of secondary hyperparathyroidism (shpt), with its active ingredient etelcalcetide playing a significant role in its effectiveness.

Parsabiv patent expiration

Parsabiv holds a total of 7 patents, with the most recent ones set to expire on 27 June, 2034, marking the earliest possible date for availability of Parsabiv generics. The patents primarily revolve around the stable liquid formulation of AMG 416 (etelcalcetide) and therapeutic agents for reducing parathyroid hormone levels. Below are the details of the patent:

EPO Oppostions filed on Parsabiv

Parsabiv dosage

Want to ask something?